Patient-Funded Trials: Opportunity or Liability?

Patient-funded trials (PFTs) are gaining traction as a means of accelerating clinical translation. However, such trials sidestep mechanisms that promote rigor, relevance, efficiency, and fairness. We recommend that funding bodies or research institutions establish mechanisms for merit review of pati...

Full description

Saved in:
Bibliographic Details
Published in:Cell stem cell 2015-08, Vol.17 (2), p.135-137
Main Authors: Wenner, Danielle Marie, Kimmelman, Jonathan, London, Alex John
Format: Article
Language:English
Subjects:
Clinical Trials as Topic - economics
Goals
Humans
Motivation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c400t-e55e18e03763cfc38c50523a9acd8d7b943216e5218a3bf50522c88494ebe9453
cites cdi_FETCH-LOGICAL-c400t-e55e18e03763cfc38c50523a9acd8d7b943216e5218a3bf50522c88494ebe9453
container_end_page 137
container_issue 2
container_start_page 135
container_title Cell stem cell
container_volume 17
creator Wenner, Danielle Marie
Kimmelman, Jonathan
London, Alex John
description Patient-funded trials (PFTs) are gaining traction as a means of accelerating clinical translation. However, such trials sidestep mechanisms that promote rigor, relevance, efficiency, and fairness. We recommend that funding bodies or research institutions establish mechanisms for merit review of patient-funded trials, and we offer some basic criteria for evaluating PFT protocols.
doi_str_mv 10.1016/j.stem.2015.07.016
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1702654263</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S193459091500315X</els_id><sourcerecordid>1702654263</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-e55e18e03763cfc38c50523a9acd8d7b943216e5218a3bf50522c88494ebe9453</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMo7rr6BzxIj15a89E0jQgii1-wsB7Wc0jTKWTptjVJhf33puzq0VMmM8-8MA9C1wRnBJPibpv5ALuMYsIzLLLYOkFzUgqeSiHEaawly1MusZyhC--3GHNBsDhHM1pQzoiUc4Q_dLDQhfRl7Gqok42zuvX3yXoYehfGzoZ90rtkZXVl2_h5vERnTSTg6vgu0OfL82b5lq7Wr-_Lp1VqcoxDCpwDKQEzUTDTGFYajjllWmpTl7WoZM4oKYBTUmpWNdOQmrLMZQ4VyJyzBbo95A6u_xrBB7Wz3kDb6g760SsiMC14TgsWUXpAjeu9d9CowdmddntFsJpMqa2aTKnJlMJCxVZcujnmj9UO6r-VXzUReDgAEK_8tuCUN9GUgdo6MEHVvf0v_wd_DHhY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1702654263</pqid></control><display><type>article</type><title>Patient-Funded Trials: Opportunity or Liability?</title><source>BACON - Elsevier - GLOBAL_SCIENCEDIRECT-OPENACCESS</source><creator>Wenner, Danielle Marie ; Kimmelman, Jonathan ; London, Alex John</creator><creatorcontrib>Wenner, Danielle Marie ; Kimmelman, Jonathan ; London, Alex John</creatorcontrib><description>Patient-funded trials (PFTs) are gaining traction as a means of accelerating clinical translation. However, such trials sidestep mechanisms that promote rigor, relevance, efficiency, and fairness. We recommend that funding bodies or research institutions establish mechanisms for merit review of patient-funded trials, and we offer some basic criteria for evaluating PFT protocols.</description><identifier>ISSN: 1934-5909</identifier><identifier>EISSN: 1875-9777</identifier><identifier>DOI: 10.1016/j.stem.2015.07.016</identifier><identifier>PMID: 26253199</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Clinical Trials as Topic - economics ; Goals ; Humans ; Motivation</subject><ispartof>Cell stem cell, 2015-08, Vol.17 (2), p.135-137</ispartof><rights>2015 Elsevier Inc.</rights><rights>Copyright © 2015 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-e55e18e03763cfc38c50523a9acd8d7b943216e5218a3bf50522c88494ebe9453</citedby><cites>FETCH-LOGICAL-c400t-e55e18e03763cfc38c50523a9acd8d7b943216e5218a3bf50522c88494ebe9453</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26253199$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wenner, Danielle Marie</creatorcontrib><creatorcontrib>Kimmelman, Jonathan</creatorcontrib><creatorcontrib>London, Alex John</creatorcontrib><title>Patient-Funded Trials: Opportunity or Liability?</title><title>Cell stem cell</title><addtitle>Cell Stem Cell</addtitle><description>Patient-funded trials (PFTs) are gaining traction as a means of accelerating clinical translation. However, such trials sidestep mechanisms that promote rigor, relevance, efficiency, and fairness. We recommend that funding bodies or research institutions establish mechanisms for merit review of patient-funded trials, and we offer some basic criteria for evaluating PFT protocols.</description><subject>Clinical Trials as Topic - economics</subject><subject>Goals</subject><subject>Humans</subject><subject>Motivation</subject><issn>1934-5909</issn><issn>1875-9777</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LxDAQhoMo7rr6BzxIj15a89E0jQgii1-wsB7Wc0jTKWTptjVJhf33puzq0VMmM8-8MA9C1wRnBJPibpv5ALuMYsIzLLLYOkFzUgqeSiHEaawly1MusZyhC--3GHNBsDhHM1pQzoiUc4Q_dLDQhfRl7Gqok42zuvX3yXoYehfGzoZ90rtkZXVl2_h5vERnTSTg6vgu0OfL82b5lq7Wr-_Lp1VqcoxDCpwDKQEzUTDTGFYajjllWmpTl7WoZM4oKYBTUmpWNdOQmrLMZQ4VyJyzBbo95A6u_xrBB7Wz3kDb6g760SsiMC14TgsWUXpAjeu9d9CowdmddntFsJpMqa2aTKnJlMJCxVZcujnmj9UO6r-VXzUReDgAEK_8tuCUN9GUgdo6MEHVvf0v_wd_DHhY</recordid><startdate>20150806</startdate><enddate>20150806</enddate><creator>Wenner, Danielle Marie</creator><creator>Kimmelman, Jonathan</creator><creator>London, Alex John</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150806</creationdate><title>Patient-Funded Trials: Opportunity or Liability?</title><author>Wenner, Danielle Marie ; Kimmelman, Jonathan ; London, Alex John</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-e55e18e03763cfc38c50523a9acd8d7b943216e5218a3bf50522c88494ebe9453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Clinical Trials as Topic - economics</topic><topic>Goals</topic><topic>Humans</topic><topic>Motivation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wenner, Danielle Marie</creatorcontrib><creatorcontrib>Kimmelman, Jonathan</creatorcontrib><creatorcontrib>London, Alex John</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cell stem cell</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wenner, Danielle Marie</au><au>Kimmelman, Jonathan</au><au>London, Alex John</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Patient-Funded Trials: Opportunity or Liability?</atitle><jtitle>Cell stem cell</jtitle><addtitle>Cell Stem Cell</addtitle><date>2015-08-06</date><risdate>2015</risdate><volume>17</volume><issue>2</issue><spage>135</spage><epage>137</epage><pages>135-137</pages><issn>1934-5909</issn><eissn>1875-9777</eissn><abstract>Patient-funded trials (PFTs) are gaining traction as a means of accelerating clinical translation. However, such trials sidestep mechanisms that promote rigor, relevance, efficiency, and fairness. We recommend that funding bodies or research institutions establish mechanisms for merit review of patient-funded trials, and we offer some basic criteria for evaluating PFT protocols.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26253199</pmid><doi>10.1016/j.stem.2015.07.016</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1934-5909
ispartof Cell stem cell, 2015-08, Vol.17 (2), p.135-137
issn 1934-5909
1875-9777
language eng
recordid cdi_proquest_miscellaneous_1702654263
source BACON - Elsevier - GLOBAL_SCIENCEDIRECT-OPENACCESS
subjects Clinical Trials as Topic - economics
Goals
Humans
Motivation
title Patient-Funded Trials: Opportunity or Liability?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T04%3A29%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Patient-Funded%20Trials:%20Opportunity%20or%20Liability?&rft.jtitle=Cell%20stem%20cell&rft.au=Wenner,%20Danielle%C2%A0Marie&rft.date=2015-08-06&rft.volume=17&rft.issue=2&rft.spage=135&rft.epage=137&rft.pages=135-137&rft.issn=1934-5909&rft.eissn=1875-9777&rft_id=info:doi/10.1016/j.stem.2015.07.016&rft_dat=%3Cproquest_cross%3E1702654263%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c400t-e55e18e03763cfc38c50523a9acd8d7b943216e5218a3bf50522c88494ebe9453%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1702654263&rft_id=info:pmid/26253199&rfr_iscdi=true